Exemestane in advanced breast cancer

Anti-Cancer Drugs

Volumn 11, Issue 8, 2000, Pages 609-616

  Buzdar, A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adverse events; Aromatase inhibitor; Exemestane; Hormone therapy; Postmenopausal breast cancer; Tolerability

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EXEMESTANE; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ADVANCED CANCER; AROMATIZATION; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN SYNTHESIS; FATIGUE; HOT FLUSH; HUMAN; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE; BREAST NEOPLASMS; DRUG TOLERANCE; ENZYME INHIBITORS; FEMALE; HUMAN; POSTMENOPAUSE;

EID: 0033787775     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200009000-00002     Document Type: Review

References (45)

1. Update on endocrine therapy for breast cancer
2. Aromatase inhibitors as potential cancer chemopreventatives
3. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: Basic and clinical appraisal
4. Hormonal therapy of breast cancer
5. Adjuvant tamoxifen therapy for early stage breast cancer and secondary primary malignancies
6. Tamoxifen and secondary tumours. An update
7. Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with megestrol acetate?
8. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Results of a survival update based on a combined analysis of data from two mature phase III trials
9. Hyperglycemia secondary to megestrol acetate for endometrial neoplasia
10. Aminoglutethimide without hydrocortisone in the treatment postmenopausal breast cancer patients
11. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer
12. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
13. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
14. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
15. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma
16. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer
17. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs tamoxifen plus aminoglutethimide and hydrocortisone
18. Decrease serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide
19. Arimidex (anastrozole): Lack of interactions with tamoxifen, antipyrine, cimetidine, and warfarin
20. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
21. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
22. Novel irreversible aromatase inhibitors
23. Novel aromatase and 5alpha-reductase inhibitors
24. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
25. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study
26. Safety, activity, and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: A phase I study
27. Exemestane (FCE 24304), a new steroidal aromatase inhibitor
28. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women
29. Exemestane experience in breast cancer treatment
30. Exemestane is superior to megestrol acetate following tamoxifen failure in post-menopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
31. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase/nhibitor
32. The minimal effective exemestane dose for endocrine activity in advanced breast cancer
33. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor
34. Phase I study of exemestane (FCE 24304), a new suicide aromatase inhibitor, in metastatic breast cancer (MBC)
35. Phase I study of exemestane (FCE 24304), a new aromatase inhibitor, in metastatic breast cancer (MBC)
36. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304)
37. Plasma changes in breast cancer patients during endocrine therapy-lipid measurements and nuclear magnetic resonance (NMR) spectroscopy
38. Antitumor efficacy of exemestane, a novel irreversible, oral, aromatase inhibitor in postmenopausal patients with metastatic breast cancer (MRC), failing tamoxifen (TAM)
39. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
40. Third-line treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study
41. Oestrogens and atherosclerotic vascular disease - Lipid factors
42. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of an overview analysis of two phase II trials